Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 13/2019

01-12-2019 | Melanoma | Melanoma

Inguinal and Ilio-inguinal Lymphadenectomy in Management of Palpable Melanoma Lymph Node Metastasis: A Long-Term Prospective Evaluation of Morbidity and Quality of Life

Authors: Michael A. Henderson, MD, FRACS, D. Gyorki, MD, FRACS, B. H. Burmeister, MD, FRANZCR, J. Ainslie, MBBS, FRANZCR, R. Fisher, PhD, J. Di Iulio, PhD, B. M. Smithers, MBBS, FRACS, A. Hong, MBBS, PhD, FRANZCR, K. Shannon, MBBS, FRACS, R. A. Scolyer, MD, FRCPA, S. Carruthers, MBBS, FRANZCR, B. J. Coventry, MBBS, PhD, FRACS, S. Babington, MBBS, FRANZCR, J. Duprat, MD, PhD, H. J. Hoekstra, MD, J. F. Thompson, MD, FRACS

Published in: Annals of Surgical Oncology | Issue 13/2019

Login to get access

Abstract

Purpose

Prospective data are lacking on long-term morbidity of inguinal lymphadenectomy including the influence of extent of surgery, use of radiotherapy, and patient factors. The aim of this study is to evaluate the effects of these factors on patient outcome, quality of life (QOL), regional symptoms, and limb volumes after inguinal or ilio-inguinal lymphadenectomy for melanoma.

Methods

Analysis of the subgroup of patients with inguinal lymph node field relapse of melanoma, treated by inguinal or ilio-inguinal lymphadenectomy in the ANZMTG/TROG randomized trial of adjuvant radiotherapy versus observation.

Results

Sixty-nine patients, 46 having undergone inguinal and 23 ilio-inguinal lymphadenectomy, with median follow-up of 73 months were analyzed. Mean limb volume increased rapidly after surgery (7% by 3 months) and continued to increase for at least another 18 months. Patients with body mass index (BMI) ≥ 25 kg/m2 had greater limb volume increase than normal-weight patients (13.3% versus 6.9%, P = 0.030). QOL improved over the first 18 months, but despite initial improvement, regional symptoms persisted long term. Type of surgery (inguinal or ilio-inguinal lymphadenectomy) had no demonstrably significant effect on limb volume (9.9% versus 13.4%, P = 0.35), QOL (P = 0.68), or regional symptoms (P = 0.65). There was no difference in overall survival between inguinal and ilio-inguinal lymphadenectomy [hazard ratio (HR) 0.75, 95% confidence interval (CI) 0.40–1.40, P = 0.43].

Conclusions

Inguinal lymphadenectomy for melanoma is a potentially morbid procedure with significant increases in limb volume. Patients report reasonable QOL but may have ongoing regional symptoms. Overweight/obesity is associated with poorer QOL, increased limb volume, and regional symptoms.
Appendix
Available only for authorised users
Literature
1.
Balch CM, Gershenwald JE, Soong S-J, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–206.CrossRef
2.
Chang SB, Askew RL, Xing Y, Weaver S, Gershenwald JE, Lee JE, et al. Prospective assessment of postoperative complications and associated costs following inguinal lymph node dissection (ILND) in melanoma patients. Ann Surg Oncol. 2010;17(10):2764–72.CrossRef
3.
Sabel MS, Griffith KA, Arora A, Shargorodsky J, Blazer DG, Rees R, et al. Inguinal node dissection for melanoma in the era of sentinel lymph node biopsy. Surgery. 2007;141(6):728–35.CrossRef
4.
Serpell JW, Carne PW, Bailey M. Radical lymph node dissection for melanoma. ANZ J Surg. 2003;73(5):294–9.CrossRef
5.
Soderman M, Thomsen JB, Sorensen JA. Complications following inguinal and ilioinguinal lymphadenectomies: a meta-analysis. J Plast Surg Hand Surg. 2016;50(6):315–20.CrossRef
6.
Van der Ploeg AP, van Akkooi AC, Schmitz PI, van Geel AN, de Wilt JH, Eggermont AM, et al. Therapeutic surgical management of palpable melanoma groin metastases: superficial or combined superficial and deep groin lymph node dissection. Ann Surg Oncol. 2011;18(12):3300–8.CrossRef
7.
Henderson MA, Burmeister BH, Ainslie J, Fisher R, Di Iulio J, Smithers BM, et al. Adjuvant lymph-node field radiotherapy versus observation only in patients with melanoma at high risk of further lymph-node field relapse after lymphadenectomy (ANZMTG 01.02/TROG 02.01): 6-year follow-up of a phase 3, randomised controlled trial. Lancet Oncol. 2015;16(9):1049–60.CrossRef
8.
Pasquali S, Spillane AJ, de Wilt JH, McCaffery K, Rossi CR, Quinn MJ, et al. Surgeons’ opinions on lymphadenectomy in melanoma patients with positive sentinel nodes: a worldwide web-based survey. Ann Surg Oncol. 2012;19(13):4322–9.CrossRef
9.
Burmeister BH, Henderson MA, Ainslie J, Fisher R, Di Iulio J, Smithers BM, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol. 2012;13(6):589–97.CrossRef
10.
11.
Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31(5):1341–6.CrossRef
12.
Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11(3):570–9.CrossRef
13.
R Core Team. R Version 3.5.1: A language and environment for statistical computing.
14.
De Vries M, Vonkeman WG, van Ginkel RJ, Hoekstra HJ. Morbidity after inguinal sentinel lymph node biopsy and completion lymph node dissection in patients with cutaneous melanoma. Eur J Surg Oncol. 2006;32(7):785–9.CrossRef
15.
Stuiver MM, Westerduin E, Meulen S ter, Vincent AD, Nieweg OE, Wouters MW. Surgical wound complications after groin dissection in melanoma patients—a historical cohort study and risk factor analysis. Eur J Surg Oncol. 2014;40(10):1284–90.CrossRef
16.
Poos HPAM, Kruijff S, Bastiaannet E, van Ginkel RJ, Hoekstra HJ. Therapeutic groin dissection for melanoma: risk factors for short term morbidity. Eur J Surg Oncol. 2009;35(8):877–83.CrossRef
17.
Cormier JN, Askew RL, Mungovan KS, Xing Y, Ross MI, Armer JM. Lymphedema beyond breast cancer: a systematic review and meta-analysis of cancer-related secondary lymphedema. Cancer. 2010;116(22):5138–49.CrossRef
18.
Hyngstrom JR, Chiang Y-J, Cromwell KD, Ross MI, Xing Y, Mungovan KS, et al. Prospective assessment of lymphedema incidence and lymphedema-associated symptoms following lymph node surgery for melanoma. Melanoma Res. 2013;23(4):290–7.PubMed
19.
Hughes TM, A’Hern RP, Thomas JM. Prognosis and surgical management of patients with palpable inguinal lymph node metastases from melanoma. Br J Surg. 2000;87(7):892–901.CrossRef
20.
De Vries M, Hoekstra HJ, Hoekstra-Weebers JE. Quality of life after axillary or groin sentinel lymph node biopsy, with or without completion lymph node dissection, in patients with cutaneous melanoma. Ann Surg Oncol. 2009;16(10):2840–7.CrossRef
21.
Ul-Mulk J, Holmich LR. Lymph node dissection in patients with malignant melanoma is associated with high risk of morbidity. Dan Med J. 2012;59(6):A4441.PubMed
22.
Cromwell KD, Chiang YJ, Armer J, Heppner PP, Mungovan K, Ross MI, et al. Is surviving enough? Coping and impact on activities of daily living among melanoma patients with lymphoedema. Eur J Cancer Care (Engl). 2015;24(5):724–33.CrossRef
23.
24.
Shaitelman SF, Cromwell KD, Rasmussen JC, Stout NL, Armer JM, Lasinski BB, et al. Recent progress in the treatment and prevention of cancer-related lymphedema. CA Cancer J Clin. 2015;65(1):55–81.CrossRef
25.
Warren AG, Brorson H, Borud LJ, Slavin SA. Lymphedema: a comprehensive review. Ann Plast Surg. 2007;59(4):464–72.CrossRef
26.
Spillane AJ, Saw RPM, Tucker M, Byth K, Thompson JF. Defining lower limb lymphedema after inguinal or ilio-inguinal dissection in patients with melanoma using classification and regression tree analysis. Ann Surg. 2008;248(2):286–93.CrossRef
27.
Testori A, Soteldo J, Powell B, Sales F, Borgognoni L, Rutkowski P, et al. Surgical management of melanoma: an EORTC Melanoma Group survey. Ecancermedicalscience. 2013;7:294.PubMedPubMedCentral
Metadata
Title
Inguinal and Ilio-inguinal Lymphadenectomy in Management of Palpable Melanoma Lymph Node Metastasis: A Long-Term Prospective Evaluation of Morbidity and Quality of Life
Authors
Michael A. Henderson, MD, FRACS
D. Gyorki, MD, FRACS
B. H. Burmeister, MD, FRANZCR
J. Ainslie, MBBS, FRANZCR
R. Fisher, PhD
J. Di Iulio, PhD
B. M. Smithers, MBBS, FRACS
A. Hong, MBBS, PhD, FRANZCR
K. Shannon, MBBS, FRACS
R. A. Scolyer, MD, FRCPA
S. Carruthers, MBBS, FRANZCR
B. J. Coventry, MBBS, PhD, FRACS
S. Babington, MBBS, FRANZCR
J. Duprat, MD, PhD
H. J. Hoekstra, MD
J. F. Thompson, MD, FRACS
Publication date
01-12-2019
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 13/2019
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-019-07810-0

Other articles of this Issue 13/2019

Annals of Surgical Oncology 13/2019 Go to the issue

Translational Research and Biomarkers

Development of a Novel Humanized Monoclonal Antibody to Secreted Frizzled-Related Protein-2 That Inhibits Triple-Negative Breast Cancer and Angiosarcoma Growth In Vivo

Translational Research and Biomarkers

Vimentin Expression in Tumor Microenvironment Predicts Survival in Pancreatic Ductal Adenocarcinoma: Heterogeneity in Fibroblast Population

Hepatobiliary Tumors

Prediction of Histopathologic Growth Patterns of Colorectal Liver Metastases with a Noninvasive Imaging Method

Pancreatic Tumors

Radiotherapy as an Adjunct to Surgery for Pancreatic Cancer: Where Are We After More Than 30 Years of Research and Trials?

Gastrointestinal Oncology

Curative-Intent Surgery for Stage IV Advanced Gastric Cancer: Who Can Undergo Surgery and What Are the Prognostic Factors for Long-Term Survival?

Breast Oncology

Breast Cancer Found Incidentally After Reduction Mammaplasty in Young Insured Women